drugset

drugset / Trial / NCT06801119

Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）

NCT06801119 ↗

Phase 1 Recruiting 30 enrolled Shenzhen MagicRNA Biotechnology Co., Ltd The First Affiliated Hospital of University of Science and Technology of China · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）

Timeline

Start: 2025-03-16
Primary completion: 2027-12-31
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HN2301	Cell therapy	—	—

Indications